The ASCO Post Staff
Linda T. Vahdat, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses results of a phase II trial designed to test the concept that targeting the tumor microenvironment by depleting copper may prevent metastases, essentially disrupting the infrastructure that contributes to tumor spread.
The ASCO Post Staff
Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that showed promising activity across a variety of RET fusion–positive cancers, including treatment-refractory gastrointestinal malignancies. This analysis highlights the need for genomic profiling to identify actionable oncogenic drivers.
The ASCO Post Staff
Matthew J. Matasar, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CHRONOS-3 trial, which showed that copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (Abstract CT001).
The ASCO Post Staff
Karen H. Vousden, PhD, of The Francis Crick Institute, and Matthew G. Vander Heiden, MD, PhD, of the Koch Institute for Integrative Cancer Research at MIT, discuss emerging evidence that diet may affect which nutrients are available to tumor cells, which can influence both tumor growth and response to therapy. Clinicians may be able to personalize dietary interventions to optimize patient care.
The ASCO Post Staff
Brian I. Rini, MD, of Vanderbilt University, discusses the IMmotion151 trial results on overall survival and the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (Abstract CT188).
